Study examines use of stent with bioabsorbable polymer

Sep 21, 2010

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

"The three-year data from the CREATE study is further evidence that biodegradable polymers represent the future of stent design," said Yaling Han, MD, the lead investigator and Director in the Department of Cardiology, Shenyang Northern Hospital (Shenyang, China.) "This study demonstrates sustained clinical safety and efficacy of based sirolimus eluting stents when used with 6 months of dual antiplatelet therapy in a 'real-world' setting."

The CREATE study was a post-marketing surveillance multi-center registry that demonstrated satisfactory angiographic (at 9 months) and clinical (at 12 and 18 months) outcomes of biodegradable polymer-based sirolimus eluting stents for real world patients. The aim of the study was to evaluate the 3-year clinical safety and efficacy outcomes in patients enrolled in the CREATE trial.

A total of 2077 patients, exclusively treated with EXCEL stents at 59 centers from 4 countries, were enrolled in the CREATE study. The recommended antiplatelet regimen was clopidogrel and aspirin for 6 months followed by chronic .

The cumulative rates of major adverse cardiac events (MACE) were 2.7% at 1 year and 4.5% at 3 years. The rate of stent thrombosis with Academic Research Consortium definitions was 0.83% at 1 year and 1.53% at 3 years. At 6 months to 3 years, prolonged therapy (> 6 months) was not beneficial in reducing cumulative hazards of MACE (5.2% vs. 4.6%, log rank p=0.629) or stent (1.5% vs. 0.6%, log rank p=0.052).

3-year outcome data will be presented during the Poster Abstracts Sessions in the Lower Level of the Washington Convention Center.

Explore further: Study hints at antioxidant treatment for high blood pressure

Provided by Cardiovascular Research Foundation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Best use of drug-eluting stents

Sep 02, 2008

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use ...

Recommended for you

Stem cells faulty in Duchenne muscular dystrophy

4 hours ago

Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the Stanford University School of Medicine have ...

Here's how the prion protein protects us

9 hours ago

The cellular prion protein (PrPC) has the ability to protect the brain's neurons. Although scientists have known about this protective physiological function for some time, they were lacking detailed knowledge ...

Regulation of maternal miRNAs in early embryos revealed

10 hours ago

The Center for RNA Research at the Institute for Basic Science (IBS) has succeeded in revealing, for the first time, the mechanism of how miRNAs, which control gene expression, are regulated in the early embryonic stage.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.